North American Prostate Cancer Diagnostics and Therapeutics Market to Reach $21,066.4 Million by 2035

North American prostate cancer diagnostics and therapeutics market was valued at $8,678.3 million in 2025 and is projected to reach $21,066.4 million by 2035, growing at a CAGR of 9.3% during the forecast period (2026–2035). Canada represents a significant component of the North American prostate cancer diagnostics and therapeutics market, supported by a high disease burden and sustained clinical demand. In 2025, an estimated 30,400 men are expected to be diagnosed with prostate cancer, accounting for 23% of all new cancer cases among men in the country. Prostate cancer also remains the second leading cause of cancer-related death in Canadian men, with approximately 5,200 projected deaths, representing 11% of total male cancer mortality. On average, 83 men are diagnosed and 14 men die each day, reinforcing the consistent need for early detection, confirmatory diagnostics, and long-term therapeutic management. These epidemiological indicators directly support demand for PSA testing, biopsy procedures, advanced imaging, and systemic treatment options across provincial healthcare systems.

Browse the full report description of “North American Prostate Cancer Diagnostics and Therapeutics Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate-Specific Antigen Test, Digital Rectal Examination, Prostate Biopsy, Imaging Techniques) by Therapeutics (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Surgery) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/north-american-prostate-cancer-diagnostic-therapeutic-market

Share of New Prostate Cancer Cases among Men in Canada, 2025 (%)

Source: Canadian Cancer Society

Key Leaders Transforming the North American Prostate Cancer Diagnostics and Therapeutics Market

The key players in the North American prostate cancer diagnostics and therapeutics market include Roche, Johnson & Johnson, Pfizer, Novartis, AstraZeneca, among others. Companies operating in the North American Prostate Cancer Diagnostics and Therapeutics market are advancing innovation through enhanced molecular testing, precision imaging technologies, and next-generation targeted therapies. Continued investment in biomarker research, radioligand treatments, and minimally invasive surgical systems is improving diagnostic accuracy and clinical outcomes. Expansion of clinical trial programs and regulatory approvals is strengthening therapeutic portfolios across early and advanced disease stages. Improvements in laboratory automation and integrated oncology care pathways are further supporting efficient patient management and sustained market growth.

• In December 2024, London Health Sciences Centre became the first hospital in Canada to administer publicly funded PLUVICTO, a Novartis radioligand therapy for advanced prostate cancer. The treatment is now covered by Ontario’s Ministry of Health as a standard option for eligible patients whose cancer has progressed despite chemotherapy. PLUVICTO targets prostate cancer cells using a radiopharmaceutical approach, aiming to improve survival with fewer side effects compared to conventional chemotherapy.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Diagnostic Technique
  • By Therapeutics
• Competitive Landscape - Roche, Johnson & Johnson, Pfizer, Novartis, AstraZeneca, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

North American Prostate Cancer Diagnostics and Therapeutics Market Report Segment

By Diagnostic Technique

• Prostate-Specific Antigen Test
• Digital Rectal Examination
• Prostate Biopsy
• Imaging Techniques

By Therapeutics

• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Targeted Therapy
• Surgery

North American Prostate Cancer Diagnostics and Therapeutics Market Report Segment by Country

• United States
• Canada

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-prostate-cancer-diagnostic-therapeutic-market